Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Following a series of high-profile market withdrawals, the obesity drug landscape has seen several new treatment options launch since 2012, However, uptake of these novel agents has been slow, suggesting suboptimal risk-benefit profiles and reflecting the poor reimbursement environment for prescription weight-loss agents. In this report, endocrinologists reveal how the current antiobesity drugs compare and which attributes the next generation should have to serve this medically important population and succeed commercially in this potentially lucrative market.

Questions Answered

  • How do endocrinologists rate current antiobesity drugs, such as Novo Nordisk’s Saxenda and Currax Pharmaceutical’s Qsymia?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What trade-offs across different clinical attributes and prices are needed from new obesity drugs to be preferred by endocrinologists?
  • How do less frequent dosing, route of administration, CV and renal benefit, and efficacy influence physician preference?

Product Description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S endocrinologists and 30 European endocrinologists fielded in April 2020.

Key drugs: Saxenda, Qsymia, Contrave/Mysimba, Xenical.

Key companies: Novo Nordisk, Vivus, Currax Pharmaceuticals, Orexigen Therapeutics.


Related Reports

Obesity/Overweight - Landscape & Forecast - Disease Landscape & Forecast

Obesity is a significant public health concern and a growing epidemic in the G7 countries. The body of evidence highlighting the physical and economic impact of obesity on society is steadily incre...

View Details

Obesity/Overweight - Current Treatment - Obesity | Treatment Algorithms: Claims Data Analysis | US | Dashboard

Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic phentermin...

View Details

Obesity/Overweight | Treatment Algorithms: Claims Data Analysis | US | 2020

Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic phentermin...

View Details

Obesity/Overweight - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis -2020

Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic phentermin...

View Details